Prognia
Drug Database
🇪🇺EU · EMAWithdrawnATC: R03AK07

Budesonide/Formoterol Teva Pharma B.V.(Budesonide;formoterol)

Asthma

Marketing Authorisation Holder: Teva Pharma B.V.

EMA Authorisation: 19/11/2014

INN: budesonide;formoterol fumarate dihydrate

Indication

Budesonide/Formoterol Teva Pharma B.V. is indicated in adults 18 years of age and older only. AsthmaBudesonide/Formoterol Teva Pharma B.V. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting ?2 adrenoceptor agonist) is appropriate:   or in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting ?2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting ?2 adrenoceptor agonists.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Budesonide/Formoterol Teva Pharma B.V. — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Ask about Budesonide/Formoterol Teva Pharma B.V.Create Free Account

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.